Search

Displaying results 4871 - 4880 of 10000 in total
  1. Drug

    Dovitinib

    go.drugbank.com/drugs/DB05928
    Investigational

    Chiron currently has three ongoing Phase I clinical trials for dovitinib. … Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers
  2. Drug

    Paclitaxel docosahexaenoic acid

    go.drugbank.com/drugs/DB05297
    Investigational

    A combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.

    Synonyms: Paclitaxel 2'-(all-cis-4,7,10,13,16,19-docosahexaenoate)
  3. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide. … Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  4. Drug

    Bosakitug

    go.drugbank.com/drugs/DB19101
    Investigational

    Bosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).

  5. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    EP3 is a target that associates with increased risk of various vascular diseases. … DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.

  6. Drug

    Foretinib

    go.drugbank.com/drugs/DB12307
    Investigational

    Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer.

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Physostigmine

    go.drugbank.com/drugs/DB00981
    Approved

    A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. … It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Gliquidone

    go.drugbank.com/drugs/DB01251
    Approved

    Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. … This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesInternational brands: Jie Shi
  9. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. … It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
  10. Drug

    Fusidic acid

    go.drugbank.com/drugs/DB02703
    ApprovedInvestigational

    It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.

    Mixtures: FUCICORT(R), FUCIDIN H %2 + %1 KREM, 30 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors